Loading...

Purified anti-mouse CD69 Antibody

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
H1dot2F3_Pure_091907
Con A-stimulated Balb/c mouse splenocytes (24 hours) stained with purified H1.2F3, followed by anti-Armenian hamster IgG FITC
  • H1dot2F3_Pure_091907
    Con A-stimulated Balb/c mouse splenocytes (24 hours) stained with purified H1.2F3, followed by anti-Armenian hamster IgG FITC
Cat # Size Price Quantity Check Availability Save
104502 500 µg 203€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F, IP - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda (?) light chain.

Application References
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Xu L, et al. 2017. Int J Biol Macromol. . 10.1016/j.ijbiomac.2017.07.090. PubMed
  2. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  3. Scutts SR, et al. 2018. Cell Rep. 25:1953. PubMed
  4. Roy S, et al. 2018. Cancer Res. 78:5600. PubMed
  5. Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed
  6. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  7. Rios–Doria J, et al. 2017. Cancer Res. 77:2686. PubMed
  8. Cui X, et al. 2017. J Immunol. 199:4066. PubMed
  9. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
  10. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  11. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  12. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  13. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  14. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  15. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  16. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  17. Wagner AK, et al. 2017. Nat Commun. 8:15627. PubMed
  18. Krovi SH, et al. 2019. Proc Natl Acad Sci U S A. 116:22252. PubMed
  19. Carpenter SM, et al. 2017. PLoS Pathog. 13:e1006704. PubMed
  20. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
  21. Clark K, et al. 2019. Front Immunol. 10:2355. PubMed
  22. Englezou PC, et al. 2018. Mol Ther Nucleic Acids. 12:118. PubMed
  23. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  24. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  25. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  26. Kroczek AL, et al. 2019. Front Immunol. 9:2806. PubMed
  27. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  28. Richards KA, et al. 2018. Front Immunol. 0.829861111. PubMed
  29. Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed
  30. Epardaud M, et al. 2008. Cancer Res. 68:2972. PubMed
  31. Kenna T, et al. 2008. Blood. 111:2091. PubMed
  32. Karmaus P, et al. 2011. J Leukoc Biol. 90:983. PubMed
  33. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
  34. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  35. Park GY, et al. 2020. Immune Netw. e43:20. PubMed
  36. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  37. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  38. Pawaria S, et al. 2020. Arthritis Rheumatol. 72:359. PubMed
  39. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
  40. Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed
  41. Sun Y, et al. 2020. J Immunol. 205:3358. PubMed
  42. Guo R, et al. 2020. Cell Res. 30:21. PubMed
  43. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
  44. Liu H, et al. 2020. J Immunol. 205:1207. PubMed
  45. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  46. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  47. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  48. Kiripolsky J, et al. 2021. J Autoimmun. 118:102608. PubMed
  49. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  50. Hsiao CC, et al. 2021. Cells. 10:. PubMed
  51. Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed
  52. Doll JR, et al. 2020. PLoS Pathog. 16:e1008296. PubMed
  53. Lu X, et al. 2021. J Exp Med. 218: . PubMed
  54. Avalos A, et al. 2022. JCI Insight. 7: . PubMed
  55. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  56. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
RRID
AB_313105 (BioLegend Cat. No. 104502)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 3    Revision Date: 04.18.2016

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account